NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
- Conditions
- Glioblastoma, Adult
- Interventions
- Device: NovoTTF-200ARadiation: 3D conformal or intensity modulated radiation therapy (IMRT)
- Registration Number
- NCT03232424
- Lead Sponsor
- Hackensack Meridian Health
- Brief Summary
This study is a prospective single arm trial designed to study the safety, feasibility and preliminary efficacy of a medical device, NovoTTF-200A used concomitantly with standard adjuvant treatment for newly diagnosed glioblastoma.
- Detailed Description
A prospective, single arm, non-randomized, open label pilot trial will enroll ten patients with histologically-confirmed newly diagnosed GBM who meet all eligibility criteria. Patients will be recruited to the study by the principal investigator (PI) or one of the co-investigators (CI) at one institution, Hackensack University Medical Center. Accrual is expected to continue for 18 months.
The protocol has a planned enrollment of 10 patients. Should patients discontinue treatment on protocol for reasons unrelated to toxicity (e.g. lost to follow-up, withdrawal of consent), additional patient (s) may be enrolled to complete enrollment.
Following maximal debulking surgery, patients will undergo a gadolinium enhanced brain MRI within 72 hours and a screening visit 2 to 4 weeks following surgery. Extent of resection will be recorded as biopsy, partial resection or gross-total resection based upon residual enhancing tumor on post-operative MRI.The day prior to XRT start, patients will have a clinic visit for training and application of the NovoTTF-200A device. During this visit, the patient will be educated regarding general use and maintenance of the device, with a particular focus upon strategies to prevent, identify and manage dermatologic adverse events (dAE). Temozolomide will be dosed nightly during XRT as per standard of care, and NovoTTF-200A will be worn continuously, removed during XRT and replaced as soon as possible thereafter.
During XRT and for 12 weeks to follow, the patient will have study visits at regular intervals (TAB A) for a physical examination and to assess toxicity and device compliance. Visits outlined in TAB A are in addition to weekly visits during radiotherapy with the treating radiation oncologist. MRI will be obtained at 4 weeks (+/-7 days) and 12 weeks (+/-7 days) following completion of XRT, and maintenance temozolomide will recommence in 5/28 day cycles as per standard of care. Objective response will be assessed as defined by the Response Assessment in Neuro-Oncology (RANO) criteria (TAB C) by the treating physician and confirmed by a second investigator.
In the case of suspected pseudoprogression, continued treatment and subsequent evaluations will help clarify whether it is true progression. Patients may continue treatment at the discretion of the investigator. If subsequent evaluations suggest that the tumor has in fact progressed, the date of progression will reflex to the date when the issue was first raised. However, if subsequent evaluations demonstrate improvement without change in therapy, the initial tumor increase may be considered pseudoprogression and response may be recorded as not evaluable for that time point. In the case of clinical progression, an unscheduled MRI will be obtained within 1 week of the investigator becoming aware of the clinical progression. No additional MRIs will be required after progression.
Temozolomide and NovoTTF-200A will continue until the final study visit, or until disease progression or unacceptable toxicity. Thereafter, temozolomide, MRI and response assessments will continue as per standard of care. Following the final study visit, the patient will be followed at a minimum of every two months for survival, either by phone or in person. If the patient is free of unacceptable toxicity attributable to NovoTTF-200A, they will be offered the opportunity to continue the device at no financial cost, but without obligation to do so.
Unacceptable toxicity includes the occurrence of device related serious adverse events or clinical and functional deterioration considered by the investigator to be prohibitive of continuing treatment. Treatment with the NovoTTF-200A device does not need to be terminated in the case of temozolomide toxicity.
The primary endpoint will be safety and tolerability of combined modality treatment with radiotherapy, temozolomide and NovoTTF-200A, based upon the incidence and severity of adverse events. Secondary endpoints will be overall survival, progression free survival and quality of life.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
-
Histologically confirmed GBM using WHO criteria.
-
Age ≥ 18 years
-
Maximal debulking surgery (at the discretion of the investigator). Biopsy alone is not exclusionary.
-
KPS ≥ 70
-
Life expectancy of at least 3 months.
-
Sexually active participants must agree to the strict use of barrier contraception.
-
Patients must be able to understand the investigational nature of the study and provide informed consent.
-
Adequate hematologic function:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ) ≥ 100 x 109/L
- Hemoglobin ≥ 10 g /dL
-
Adequate liver function
- Total bilirubin ≤ 1.5 x ULN
- AST and ALT ≤ 2.5 x ULN
-
Adequate renal function
a. Creatinine ≤ 1.25 x ULN
-
International normalized ratio (INR) or PT and activated partial thromboplastin time (aPTT): 1.5 x ULN (except for subjects receiving anticoagulation therapy). Use of anticoagulants is permitted as long as the INR or aPTT are within therapeutic limits (according to the medical standard of the institution).
-
Active participation in another clinical treatment trial. Concomitant protocols for data or tissue collection without intervention are permitted.
-
Any prior treatment for GBM aside from surgery, including carmustine wafers.
-
Women who are pregnant or nursing.
-
Severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation, NovoTTF-200A device use or interfere with interpretation of trial results and, in the judgment of the investigator, would make the patient inappropriate for entry into the trial. This includes but not limited to:
- Patients with inadequately healed surgical incisions or other dermatologic scalp toxicity at baseline (grade 2 or higher, as defined in Section VIII) upon which transducer leads may require placement.
- Known HIV or other immunosuppressive disease, chronic hepatitis B or hepatitis C
- Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of the protocol.
-
Implanted pacemaker, programmable shunt, cardiac defibrillator, deep brain stimulator, other implanted electronic devices in the brain or documented clinically significant arrhythmias.
-
Infratentorial glioblastoma.
-
Past hypersensitivity reaction to temozolomide or DTIC.
-
Psychiatric illness that compromises the informed consent process, at the discretion of the investigator.
-
Inability or unwillingness to return for required visits.
-
Previous cytotoxic therapy within the last 5 years.
-
Inability to begin temozolomide concomitant to radiation therapy, for reasons 4 or 7 above.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description NovoTTF-200A + Temozolomide Chemoradiation NovoTTF-200A NovoTTF-200A, concomitant with radiotherapy and temozolomide, as front-line therapy for glioblastoma NovoTTF-200A + Temozolomide Chemoradiation 3D conformal or intensity modulated radiation therapy (IMRT) NovoTTF-200A, concomitant with radiotherapy and temozolomide, as front-line therapy for glioblastoma NovoTTF-200A + Temozolomide Chemoradiation Temozolomide NovoTTF-200A, concomitant with radiotherapy and temozolomide, as front-line therapy for glioblastoma
- Primary Outcome Measures
Name Time Method Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] 24 months Safety and tolerability of combined modality treatment with radiotherapy, temozolomide and NovoTTF-200A based upon the incidence and severity of adverse events.
- Secondary Outcome Measures
Name Time Method Overall survival time From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months Assessed from NovoTTF-200A start date to date of death of any cause. Patients will be censored at the time that they are last known to be alive (if withdrawn or lost to follow-up).
Progression free survival at 6 months From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months Assessed from NovoTTF-200A start date to the date of the first observation of clinical or radiographic disease progression or death due to any cause. Patients will be censored at the time they are last known to be alive and progression free (if withdrawn or lost to follow-up).
Quality of life assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of life questionnaire (QLQ-C30) 24 months Change from baseline at each measure will be calculated for each subscale domain and symptom scale in the questionnaire. The QLQ-C30 incorporates five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnea, loss of appetite, insomnia, constipation and diarrhea) and perceived financial impact of the disease. The response scale to each question ranges from 1 (Not at All) to 4 (Very Much). For each subscale domain and symptom scale, the change from baseline will summarized as mean (SD) or median (interquartile range), as appropriate.
Quality of life assessed using a European Organization for Research and Treatment of Cancer (EORTC) Brain Cancer questionnaire (BN20) 24 months Change from baseline at each measure will be calculated for each subscale domain and symptom scale in the questionnaire. The questionnaire includes 20 items assessing future uncertainty, visual disorder, motor dysfunction, communication deficit and other disease symptoms (e.g. headaches and seizures) and treatment toxicities (e.g. hair loss). The response scale to each question ranges from 1 (Not at All) to 4 (Very Much). For each subscale domain and symptom scale, the change from baseline will summarized as mean (SD) or median (interquartile range), as appropriate.
Trial Locations
- Locations (1)
John Theurer Cancer Center at Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States